Business
OBD joins ALS Biomarker study sponsored by MTPA
OBD joins ALS Biomarker study sponsored by MTPA.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 0381Y Oxford BioDynamics PLC 03 May 2019 \n\n \n3 May 2019\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n\noxford biodynamics JOINS ALS BIOMARKER STUDY Sponsored by mitsubishi tanabe pharma america \n \nProprietary Technology Platform to Assess Biomarker Panels in People with ALS\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to note today's announcement by Mitsubishi Tanabe Pharma America, Inc. (MTPA) that Oxford BioDynamics has joined the REFINE-ALS study, which was designed to identify and measure specific biomarkers in people with amyotrophic lateral sclerosis (ALS). Using an innovative technology platform to evaluate epigenetic and protein biomarkers, the company's analyses may offer insights on disease progression and treatment effect.\n \nREFINE-ALS is sponsored by MTPA and led by Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI). Biomarkers including oxidative stress, inflammation, neuronal injury/death and muscle injury, as well as clinical assessments, will be obtained from up to 300 patients in the U.S. prior to initiating treatment with edaravone, at start of treatment and at pre-specified time points for 24 weeks.\n \nOxford BioDynamics will evaluate biomarker panels utilizing EpiSwitchTM. This proprietary technology platform assesses a novel class of epigenetic biomarkers known as chromosome conformation signatures, which are aimed at understanding the rate of disease progression.\n \nAt least 30 genes are believed to play a role in ALS, but more information is needed on their potential impact in ALS. This, combined with the lack of reliable laboratory tests to identify ALS, contributes to poor disease diagnosis, which may impact treatment.1\n \nAll participants in the prospective, observational, longitudinal, multicenter trial will be U.S. patients prescribed edaravone, commercially available in the U.S. since August 2017. Patient biomarker data and disease progression assessments will be compared to samples stored at biorepositories and progression models, respe...